Literature DB >> 19760483

National questionnaire survey of TMA.

Naomi Ito1, Hideo Wada2, Masanori Matsumoto3, Yoshihiro Fujimura3, Mitsuru Murata4, Takashi Izuno5, Minoru Sugita6, Yasuo Ikeda7.   

Abstract

A questionnaire survey of Japanese patients with thrombotic microangiopathy (TMA) was carried out to investigate the frequency, laboratory abnormalities, and outcome in 2004. Out of 185 patients, there were 13 with familial TMA and 172 with acquired TMA. In acquired TMA, there were 66 with Escherichia coli O-157 infection (O-157)-related TMA, 35 with ADAMTS13-related TMA, and 22 with other types of TMA. The frequency of TMA in O-157-related TMA was high in patients from 0- to 15-year-old, and acquired TMA without O-157 was frequently observed in patients ranging from 31 to 65 years of age. In the treatment of acquired TMA, including plasma exchange (PE), steroid, antiplatelet agent, and anticoagulant, PE was carried out in 94.3% of ADAMTS13-related TMA, 77.3% of other TMA, and 7.6% of O-157-related TMA. The efficacy of PE and steroid therapy tended to be higher in ADAMTS13 TMA than in other types of TMA. The complete remission rate is the highest in O-157 TMA. The mortality rate was the lowest for O-157 TMA, and this rate also tended to be lower in ADAMTS13-related TMA than in other types of TMA. However, the determination of ADAMTS13 was not universal in Japan at the time of this questionnaire.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760483     DOI: 10.1007/s12185-009-0421-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  24 in total

1.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Authors:  Sarah L Allford; Beverley J Hunt; Peter Rose; Samuel J Machin
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

2.  Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.

Authors:  Seiji Kato; Masanori Matsumoto; Tomomi Matsuyama; Ayami Isonishi; Hisahide Hiura; Yoshihiro Fujimura
Journal:  Transfusion       Date:  2006-08       Impact factor: 3.157

Review 3.  Thrombotic thrombocytopenic purpura: a review.

Authors:  R M Bukowski
Journal:  Prog Hemost Thromb       Date:  1982

4.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

5.  Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura.

Authors:  T W Chow; N A Turner; M Chintagumpala; P D McPherson; L H Nolasco; L Rice; J D Hellums; J L Moake
Journal:  Am J Hematol       Date:  1998-04       Impact factor: 10.047

Review 6.  Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.

Authors:  Eric Chun-Yet Lian
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

Review 7.  The management of thrombotic thrombocytopenic purpura in 2005.

Authors:  Gail Rock
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

8.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

9.  The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  Masanori Matsumoto; Hideo Yagi; Hiromichi Ishizashi; Hideo Wada; Yoshihiro Fujimura
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

10.  Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.

Authors:  H Wada; T Kaneko; M Ohiwa; M Tanigawa; T Hayashi; S Tamaki; N Minami; K Deguchi; K Suzuki; T Nakano
Journal:  Am J Hematol       Date:  1993-10       Impact factor: 10.047

View more
  4 in total

1.  A second national questionnaire survey of TMA.

Authors:  Naomi Ito-Habe; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2010-06-05       Impact factor: 2.490

2.  Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation.

Authors:  Takeshi Matsumoto; Xinping Fan; Eiji Ishikawa; Masaaki Ito; Keishirou Amano; Hidemi Toyoda; Yoshihiro Komada; Kohshi Ohishi; Naoyuki Katayama; Yoko Yoshida; Masanori Matsumoto; Yoshihiro Fujimura; Makoto Ikejiri; Hideo Wada; Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2014-08-19       Impact factor: 2.490

3.  Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome.

Authors:  Naomi Ito-Habe; Hideo Wada; Takeshi Matsumoto; Kohshi Ohishi; Hidemi Toyoda; Eiji Ishikawa; Shinsuke Nomura; Yoshihiro Komada; Masaaki Ito; Tsutomu Nobori; Naoyuki Katayama
Journal:  Int J Hematol       Date:  2010-12-09       Impact factor: 2.490

Review 4.  Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy.

Authors:  Hideo Wada; Takeshi Matsumoto; Kei Suzuki; Hiroshi Imai; Naoyuki Katayama; Toshiaki Iba; Masanori Matsumoto
Journal:  Thromb J       Date:  2018-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.